Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
September 28, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to COVID-19...
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
August 22, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse...
Resverlogix Announces Appointment of New Chief Scientific Officer
August 15, 2022 18:00 ET
|
Resverlogix Corp
CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr....
Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders
June 21, 2022 23:30 ET
|
Resverlogix Corp
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary,...
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
June 08, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D...
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study
May 09, 2022 07:15 ET
|
Resverlogix Corp
CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company") (TSX:RVX), in partnership with EVERSANA™, today announced that the U.S. Food and Drug...
Resverlogix Announces One-Year Extension of Debenture
April 19, 2022 17:05 ET
|
Resverlogix Corp
CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) announced today that it has closed a one-year extension of Company’s US$6.0 million...
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
March 17, 2022 07:15 ET
|
Resverlogix Corp
CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “BET Protein Inhibition for Pulmonary Arterial...
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada
February 17, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that the first Brazilian site has been initiated for its Phase 2b study to evaluate...
Resverlogix宣布在加拿大开发的一种有前景的新冠肺炎药物的2b期临床试验中开始患者招募和给药
January 19, 2022 03:58 ET
|
Resverlogix Corp
阿尔伯塔省卡尔加里, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp.（以下简称“Resverlogix”）（多伦多证券交易所股票代码： RVX）今天高兴地宣布，在埃德蒙顿阿尔伯塔大学医院一个临床中心进行的一项2b阶段研究已开始患者招募和给药。试验将对apabetalone作为新冠肺炎潜在口服药物的安全性和疗效进行评估。 ...